Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. - Bissonnette, R.; Luger, T.; Thaçi, D.; Toth, D.; Messina, I.; You, R.; Guana, A.; Fox, T.; Papavassilis, C.; Gilloteau, I.; Mrowietz, U. (British Journal of Dermatology, 2017)